HOME >> BIOLOGY >> NEWS
Orexigen reports positive phase II results for Excalia Combination-Therapy to treat obesity

San Diego, CA, 11:00 am EDT, October 22, 2006 OREXIGENTM Therapeutics, Inc., a privately held clinical-stage neuroscience company developing novel strategic approaches to the treatment of obesity, today announced that ExcaliaTM, a combination of two centrally-acting medications intended to provide and sustain clinically important weight loss, demonstrated significant weight loss in a six month, double-blind, phase IIa clinical study. The magnitude of weight reduction exceeded that seen with placebo. The findings showed that patients completing the blinded 24-week phase lost on average 9.2% of their weight from baseline using Excalia compared to an average of 0.4% weight loss from baseline for patients using placebo. The study results further demonstrate that weight loss continued through an additional 24 week open-label period achieving an average weight loss of 12% from baseline by 48 weeks. These top line phase IIa data for Excalia were presented at the annual meeting of the North American Association for the Study of Obesity (NAASO) in Boston.

"Excalia is designed to achieve an aggressive weight loss trajectory and then to delay the typical weight loss 'plateau' by offsetting one of the body's natural compensatory pathways. These phase II data suggest a level of efficacy that exceeded our expectations in relation to existing approaches," said Gary Tollefson, M.D., Ph.D., OREXIGEN president and CEO. "Excalia is designed to act on a specific reciprocally paired group of hypothalamic neurons that we believe will yield a clinically meaningful weight loss trajectory among significantly overweight individuals. We believe that these positive data support our theoretical approach."

Excalia is a proprietary combination of bupropion, a dopamine and norepinephrine reuptake inhibitor, plus zonisamide, an approved anticonvulsant medication. OREXIGEN's preclinical research suggests that combining these two central nervous system d
'"/>

Contact: Stephen Gendel
sgendel@biocompartners.com
212-918-4650
BioCom Partners
22-Oct-2006


Page: 1 2 3

Related biology news :

1. ChemGenex reports successful personalized dosing of Quinamed at ASCO
2. 1 month post launch, Interactive Autism Network reports 13,000 participants
3. Biosite reports on presentation of preliminary data from sepsis program
4. Biolex reports potential for more potent, efficacious antibodies in Nature Biotechnology
5. Dinosaurs climate shifted too, reports show
6. The New England Journal of Medicine reports data on eculizumab for the treatment of PNH
7. Portion distortion may contribute to expanding waistlines, study reports
8. Study reports findings on lung cancer death rates in never smokers
9. Breast implants not associated with cancer risk, study reports
10. Paper reports discovery of virus implicated in genetics of prostate cancer
11. First analysis of FDAs mifepristone adverse event reports

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/31/2018)... ... August 30, 2018 , ... ... Research. Jacklyn Novak, infrared materials engineer, LightPath Technologies. In the future, these names ... just celebrated her 100th birthday. Today, they are among 26 scientists whose work ...
(Date:8/29/2018)... SAN JOSE, Calif. (PRWEB) , ... August 28, ... ... leader in cluster and cloud infrastructure automation software, announced that Data In Science ... , The HudsonAlpha Institute for Biotechnology is a non-profit genomics and ...
(Date:8/29/2018)... ... August 28, 2018 , ... ... the full power of positron emission tomography (PET), today launched its proprietary ... is helping clinicians and researchers study and cure debilitating diseases, earlier, and ...
Breaking Biology News(10 mins):
(Date:9/12/2018)... (PRWEB) , ... September 11, 2018 , ... ... proud to add flat sheet Forward Osmosis (FO) membranes from Fluid Technology Solutions ... membranes manufactured by FTS H2O are constructed from cellulose triacetate (CTA) material. The ...
(Date:9/7/2018)... (PRWEB) , ... September 06, 2018 , ... ... device compliance and commercialization, is releasing the agenda for its upcoming user conference. ... life science industries discussing the latest challenges, opportunities, and approaches to regulatory compliance ...
(Date:8/31/2018)... ... August 29, 2018 , ... A recent expedition ... Southampton and the Institute of Industrial Science, the University of Tokyo, demonstrated how ... the exploration and study of hard to reach deep sea ecosystems, like intermittently ...
(Date:8/29/2018)... ... August 28, 2018 , ... Inc. Magazine ... has been ranked in 1138th place on the 27th annual Inc. 5000, the ... list represents the most successful companies within the American economy’s most dynamic segment ...
Breaking Biology Technology:
Cached News: